Total Payments
$32,721
2024 Payments
$1,969
Companies
16
Transactions
40
Medicare Patients
1,811
Medicare Billing
$316,396
Payment Breakdown by Category
Consulting$18,306 (55.9%)
Research$8,197 (25.1%)
Other$4,960 (15.2%)
Food & Beverage$1,214 (3.7%)
Education$23.93 (0.1%)
Travel$20.00 (0.1%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $18,306 | 10 | 55.9% |
| Unspecified | $8,197 | 8 | 25.1% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $4,960 | 2 | 15.2% |
| Food and Beverage | $1,214 | 17 | 3.7% |
| Education | $23.93 | 1 | 0.1% |
| Travel and Lodging | $20.00 | 2 | 0.1% |
Payments by Type
General
$24,524
32 transactions
Research
$8,197
8 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | $7,903 | 6 | $0 (2023) |
| Novartis Pharmaceuticals Corporation | $5,995 | 2 | $0 (2024) |
| PFIZER INC. | $5,665 | 10 | $0 (2023) |
| Seattle Genetics, Inc. | $3,639 | 6 | $0 (2019) |
| EMD Serono, Inc. | $3,000 | 1 | $0 (2020) |
| GENZYME CORPORATION | $2,643 | 2 | $0 (2019) |
| Janssen Scientific Affairs, LLC | $1,768 | 2 | $0 (2022) |
| Exelixis Inc. | $1,470 | 1 | $0 (2020) |
| Eli Lilly and Company | $180.45 | 1 | $0 (2018) |
| Astellas Pharma Global Development | $131.60 | 1 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $1,969 | 2 | Novartis Pharmaceuticals Corporation ($1,838) |
| 2023 | $4,480 | 4 | PFIZER INC. ($2,260) |
| 2022 | $6,515 | 5 | Novartis Pharmaceuticals Corporation ($4,157) |
| 2021 | $4,641 | 4 | AstraZeneca Pharmaceuticals LP ($3,608) |
| 2020 | $4,618 | 6 | EMD Serono, Inc. ($3,000) |
| 2019 | $8,090 | 13 | Seattle Genetics, Inc. ($3,639) |
| 2018 | $413.42 | 4 | Eli Lilly and Company ($180.45) |
| 2017 | $1,995 | 2 | AstraZeneca Pharmaceuticals LP ($1,995) |
All Payment Transactions
40 individual payment records from CMS Open Payments — Page 1 of 2
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 09/24/2024 | Novartis Pharmaceuticals Corporation | PLUVICTO (Drug) | Consulting Fee | Cash or cash equivalent | $1,837.50 | General |
| Category: Oncology | ||||||
| 08/28/2024 | Astellas Pharma Global Development | Xtandi (Drug) | Food and Beverage | In-kind items and services | $131.60 | General |
| Category: Oncology | ||||||
| 10/22/2023 | PFIZER INC. | TALZENNA (Drug) | — | In-kind items and services | $940.00 | Research |
| Study: TALAZOPARIB CLINICAL PUBLICATION PROGRAM • Category: ONCOLOGY | ||||||
| 10/02/2023 | AstraZeneca Pharmaceuticals LP | LYNPARZA (Drug) | Consulting Fee | Cash or cash equivalent | $2,220.00 | General |
| Category: Oncology | ||||||
| 05/10/2023 | PFIZER INC. | TALZENNA (Drug) | — | In-kind items and services | $990.00 | Research |
| Study: TALAZOPARIB CLINICAL PUBLICATION PROGRAM • Category: ONCOLOGY | ||||||
| 02/14/2023 | PFIZER INC. | TALZENNA (Drug) | — | In-kind items and services | $330.00 | Research |
| Study: TALAZOPARIB CLINICAL PUBLICATION PROGRAM • Category: ONCOLOGY | ||||||
| 12/19/2022 | Janssen Scientific Affairs, LLC | — | Consulting Fee | Cash or cash equivalent | $757.50 | General |
| 10/01/2022 | Novartis Pharmaceuticals Corporation | — | — | In-kind items and services | $4,157.00 | Research |
| Study: PUBLICATION SUPPORT PROVIDED IN CONNECTION WITH HEOR RESEARCH | ||||||
| 08/30/2022 | PFIZER INC. | TALZENNA (Drug) | — | In-kind items and services | $940.00 | Research |
| Study: TALAZOPARIB CLINICAL PUBLICATION PROGRAM • Category: ONCOLOGY | ||||||
| 05/03/2022 | PFIZER INC. | TALZENNA (Drug) | — | In-kind items and services | $330.00 | Research |
| Study: TALAZOPARIB CLINICAL PUBLICATION PROGRAM • Category: ONCOLOGY | ||||||
| 05/03/2022 | PFIZER INC. | TALZENNA (Drug) | — | In-kind items and services | $330.00 | Research |
| Study: TALAZOPARIB CLINICAL PUBLICATION PROGRAM • Category: ONCOLOGY | ||||||
| 11/30/2021 | Janssen Scientific Affairs, LLC | ERLEADA (Drug) | Consulting Fee | Cash or cash equivalent | $1,010.00 | General |
| Category: Oncology | ||||||
| 11/22/2021 | AstraZeneca Pharmaceuticals LP | LYNPARZA (Drug) | Consulting Fee | Cash or cash equivalent | $1,942.50 | General |
| Category: Oncology | ||||||
| 04/02/2021 | Myovant Sciences Inc. | ORGOVYX (Drug) | Education | In-kind items and services | $23.93 | General |
| Category: HORMONE THERAPY | ||||||
| 03/21/2021 | AstraZeneca Pharmaceuticals LP | LYNPARZA (Drug) | Consulting Fee | Cash or cash equivalent | $1,665.00 | General |
| Category: Oncology | ||||||
| 11/10/2020 | EMD Serono, Inc. | Bavencio (Drug) | Consulting Fee | Cash or cash equivalent | $3,000.00 | General |
| Category: Oncology | ||||||
| 08/20/2020 | Exelixis Inc. | Cabometyx (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,470.00 | General |
| Category: Oncology | ||||||
| 05/06/2020 | SANOFI-AVENTIS U.S. LLC | JEVTANA (Drug) | Food and Beverage | In-kind items and services | $20.12 | General |
| Category: Oncology | ||||||
| 04/21/2020 | Coherus Biosciences Inc. | Udenyca (Biological) | Food and Beverage | In-kind items and services | $15.05 | General |
| Category: Granulocyte colony stimulating factor | ||||||
| 04/07/2020 | SANOFI-AVENTIS U.S. LLC | JEVTANA (Drug) | Food and Beverage | In-kind items and services | $20.78 | General |
| Category: Oncology | ||||||
| 02/13/2020 | PFIZER INC. | — | Food and Beverage | In-kind items and services | $91.60 | General |
| 11/02/2019 | Seattle Genetics, Inc. | — | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $3,490.00 | General |
| 11/02/2019 | Seattle Genetics, Inc. | — | Food and Beverage | In-kind items and services | $55.44 | General |
| 11/02/2019 | Seattle Genetics, Inc. | — | Food and Beverage | In-kind items and services | $53.08 | General |
| 11/02/2019 | Seattle Genetics, Inc. | — | Food and Beverage | In-kind items and services | $20.27 | General |
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| PUBLICATION SUPPORT PROVIDED IN CONNECTION WITH HEOR RESEARCH | Novartis Pharmaceuticals Corporation | $4,157 | 1 |
| TALAZOPARIB CLINICAL PUBLICATION PROGRAM | PFIZER INC. | $3,860 | 6 |
| A DOUBLE-BLINDED, PLACEBO-CONTROLLED, RANDOMIZED PHASE II STUDY OF ENZALUTAMIDE WITH OR WITHOUT THE PI3 KINASE-MTOR INHIBITOR LY3023414 IN MEN WITH METASTATIC CASTRATION RESISTANT PROSTATE CANCER | Eli Lilly and Company | $180.45 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 5 | 517 | 1,070 | $292,400 | $89,196 |
| 2022 | 5 | 488 | 948 | $265,377 | $85,090 |
| 2021 | 5 | 414 | 871 | $245,353 | $78,719 |
| 2020 | 8 | 392 | 868 | $230,582 | $63,391 |
Total Patients
1,811
Total Services
3,757
Medicare Billing
$316,396
Procedure Codes
23
All Medicare Procedures & Services
23 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2023 | 193 | 495 | $124,245 | $37,038 | 29.8% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2023 | 134 | 315 | $110,880 | $36,060 | 32.5% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Facility | 2023 | 60 | 60 | $28,260 | $8,382 | 29.7% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Facility | 2023 | 70 | 105 | $20,370 | $5,279 | 25.9% |
| G2212 | Prolonged office or other outpatient evaluation and management service(s) beyond the maximum required time of the primary procedure which has been selected using total time on the date of the primary service; each additional 15 minutes by the physician or | Facility | 2023 | 60 | 95 | $8,645 | $2,437 | 28.2% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2022 | 135 | 315 | $110,880 | $37,899 | 34.2% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2022 | 196 | 427 | $107,177 | $33,033 | 30.8% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Facility | 2022 | 51 | 51 | $24,021 | $7,434 | 30.9% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Facility | 2022 | 67 | 94 | $18,236 | $5,082 | 27.9% |
| G2212 | Prolonged office or other outpatient evaluation and management service(s) beyond the maximum required time of the primary procedure which has been selected using total time on the date of the primary service; each additional 15 minutes by the physician or | Facility | 2022 | 39 | 61 | $5,063 | $1,643 | 32.5% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Facility | 2021 | 182 | 461 | $115,711 | $36,877 | 31.9% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Facility | 2021 | 113 | 265 | $93,280 | $30,433 | 32.6% |
| 99205 | New patient outpatient visit, total time 60-74 minutes | Facility | 2021 | 42 | 42 | $19,782 | $6,226 | 31.5% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Facility | 2021 | 55 | 76 | $14,744 | $4,426 | 30.0% |
| G2212 | Prolonged office or other outpatient evaluation and management service(s) beyond the maximum required time of the primary procedure which has been selected using total time on the date of the primary service; each additional 15 minutes by the physician or | Facility | 2021 | 22 | 27 | $1,836 | $757.10 | 41.2% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Facility | 2020 | 188 | 530 | $126,670 | $33,759 | 26.7% |
| 99215 | Established patient office or other outpatient, visit typically 40 minutes | Facility | 2020 | 103 | 206 | $69,010 | $18,846 | 27.3% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2020 | 18 | 33 | $9,009 | $3,018 | 33.5% |
| 99205 | New patient office or other outpatient visit, typically 60 minutes | Facility | 2020 | 21 | 21 | $9,429 | $2,811 | 29.8% |
| 99232 | Subsequent hospital inpatient care, typically 25 minutes per day | Facility | 2020 | 21 | 36 | $6,912 | $2,279 | 33.0% |
| 99204 | New patient office or other outpatient visit, typically 45 minutes | Facility | 2020 | 14 | 14 | $4,998 | $1,423 | 28.5% |
| 99442 | Physician telephone patient service, 11-20 minutes of medical discussion | Facility | 2020 | 15 | 16 | $2,334 | $714.56 | 30.6% |
| 99213 | Established patient office or other outpatient visit, typically 15 minutes | Facility | 2020 | 12 | 12 | $2,220 | $540.42 | 24.3% |
About Dr. Song Zhao, MD
Dr. Song Zhao, MD is a Hematology & Oncology healthcare provider based in Seattle, Washington. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 02/24/2010. The National Provider Identifier (NPI) number assigned to this provider is 1346562816.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Song Zhao, MD has received a total of $32,721 in payments from pharmaceutical and medical device companies, with $1,969 received in 2024. These payments were reported across 40 transactions from 16 companies. The most common payment nature is "Consulting Fee" ($18,306).
As a Medicare-enrolled provider, Zhao has provided services to 1,811 Medicare beneficiaries, totaling 3,757 services with total Medicare billing of $316,396. Data is available for 4 years (2020–2023), covering 23 distinct procedure/service records.
Ad
Practice Information
- Specialty Hematology & Oncology
- Location Seattle, WA
- Active Since 02/24/2010
- Last Updated 04/30/2021
- Taxonomy Code 207RH0003X
- Entity Type Individual
- NPI Number 1346562816
Products in Payments
- LYNPARZA (Drug) $5,828
- TALZENNA (Drug) $3,950
- Bavencio (Drug) $3,000
- JEVTANA (Drug) $2,684
- IMFINZI (Drug) $2,170
- PLUVICTO (Drug) $1,838
- Cabometyx (Drug) $1,470
- ERLEADA (Drug) $1,010
- Xtandi (Drug) $131.60
- SpaceOAR (Device) $118.50
- ZYTIGA (Drug) $33.97
- ORGOVYX (Drug) $23.93
- Udenyca (Biological) $15.05
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Hematology & Oncology Doctors in Seattle
Mr. John Pesando, Md, MD
Hematology & Oncology — Payments: $12.8M
Hematology & Oncology $12.8M
John Pagel, Md Phd, MD PHD
Hematology & Oncology — Payments: $1.3M
Hematology & Oncology $1.3M
Dr. Langdon Miller, Md, MD
Hematology & Oncology — Payments: $674,815
Hematology & Oncology $674,815
Dr. Vijayakrishna Gadi, M.d. Phd, M.D. PHD
Hematology & Oncology — Payments: $534,649
Hematology & Oncology $534,649
Barbara Konkle, Md, MD
Hematology & Oncology — Payments: $331,390
Hematology & Oncology $331,390
Dr. Jill Johnsen, Md, MD
Hematology & Oncology — Payments: $291,732
Hematology & Oncology $291,732